SABS
SAB Biotherapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website abbiotherapeutics.com
- Employees(FY) 56
- ISIN US78397T2024
Performance
-9.25%
1W
-25.61%
1M
-33.88%
3M
-59.67%
6M
-47.2%
YTD
-57.34%
1Y
Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Technical Analysis of SABS 2024-05-10
Overview:
In analyzing the technical indicators for SABS stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potenti...
Recent News & Updates
- 2024-05-05 19:15
- 2024-04-15 19:15
SAB Biotherapeutics Provides SAB-142 Trial Update(Globenewswire)
- 2024-04-07 19:15
SAB Biotherapeutics to Present at INNODIA Annual Meeting(Globenewswire)
- 2024-04-03 19:15
- 2024-03-28 19:15
- 2024-03-24 22:15
- 2024-02-22 19:00
- 2024-02-07 19:00
- 2024-02-01 18:30
SAB Biotherapeutics Announces Executive Leadership Change(Globenewswire)
- 2024-01-23 04:58
- 2024-01-07 15:00
- 2024-01-07 10:00
- 2024-01-07 10:00
- 2024-01-07 05:00
- 2024-01-07 02:00
Aangan Aapno Kaa Serial 2024 Updates , SonyLIV App Streaming Online(Indian Television and OTT News)
- 2024-01-06 21:00
Hum Sab PM Hain: INDI Alliance a non-starter(Statetimes)
- 2024-01-05 05:37
- 2024-01-02 16:30
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split(GlobeNewswire)
- 2024-01-02 03:30
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split(globenewswire)
- 2023-11-29 13:29
- 2023-11-29 07:30
- 2023-11-28 18:30
- 2023-11-20 07:30
- 2023-11-19 18:30
- 2023-11-14 13:35
- 2023-11-14 07:30
- 2023-11-14 07:15
- 2023-11-13 18:30
- 2023-11-13 18:15
- 2023-11-08 18:30
Page 1 of 4
previousnext